Related Experiment Video
Updated: Aug 10, 2026
Orthotopic Liver Transplantation in Rats
Published on: July 1, 2012
Liver transplantation in hepatitis C virus-related cirrhosis
J Ziolkowski1, M Niewczas, G Senatorski
1Department of Immunology, Transplant Medicine, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Insights
Hepatitis C virus (HCV) recurrence after liver transplantation often impairs graft function. This study found immunosuppression regimens did not impact outcomes in HCV-infected liver transplant recipients.
Area of Science:
- Hepatology
- Transplantation Immunology
Background:
- Hepatitis C virus (HCV) infection is a primary cause of end-stage liver disease and a common reason for liver transplantation.
- HCV recurrence post-liver transplant is frequent and can lead to graft dysfunction.
Purpose of the Study:
- To evaluate factors influencing outcomes in patients undergoing liver transplantation for HCV-related liver disease.
- To assess the impact of immunosuppression and acute rejection on HCV recurrence and graft function.
Main Methods:
- Retrospective analysis of 164 adult liver transplant recipients (December 1994-December 2002).
- Focus on 25 patients with HCV-related liver disease, analyzing graft function, liver tests, immunosuppression, and rejection episodes post-transplant.
- Follow-up averaged 24.8 months.
Main Results:
- HCV reinfection led to graft function deterioration in 64% of cases, with a mean time of 4.5 months.
- Neither induction nor maintenance immunosuppression significantly affected outcomes in HCV-infected recipients.
- HCV-infected recipients showed higher aminotransferase levels.
- High-dose steroid use for acute rejection correlated with a trend towards earlier HCV hepatitis recurrence.
Conclusions:
- HCV recurrence significantly impacts liver graft function post-transplantation.
- Current immunosuppression strategies do not appear to alter outcomes in HCV-infected liver transplant recipients.
- Further research into managing HCV recurrence and optimizing immunosuppression is warranted.
Abstract:
End-stage liver disease associated with HCV infection has become one of the leading indications for liver transplantation and it is the most common disease recurring after liver transplantation. The aim of this retrospective study was to asses factors potentially affecting outcome in patients transplanted for HCV-related liver disease. Among 164 adult patients who underwent orthotopic liver transplantation from December 1994 to December 2002, 134 survived >2 months, including 25 with HCV-related liver disease. Mean follow-up after LTx was 24.8 months (range, 2.1-99.4). Anti-HCV was negative in all donors. The parameters considered in our analysis were: the course, outcome, and liver function tests at 1-year follow-up after HCV reinfection: the potential impact of maintenance and induction immunosuppressive regimens; and episodes of acute rejection. Deterioration of graft function because of HCV reinfection occurred in 16 patients (64%). Mean time for deterioration of liver function related to reinfection was 4.5 months (range, 0.83-23). Induction and maintenance immunosuppression did not affect outcome of HCV-infected liver transplant recipients. Aminotransferases were significantly higher among HCV-infected recipients than among the other patients in our series. There was a slight tendency for earlier recurrence of HCV hepatitis among patients treated with high-dose steroids because of acute rejection.
Related Concept Videos
01:25Hepatitis
01:23Cirrhosis I: Introduction
01:24Cirrhosis II: Pathophysiology